|  |  |  |  |
| --- | --- | --- | --- |
| **Supplementary Table 1.** List of the SNPs analysed | | | |
| **Gene** | **SNP ID** | **Polymorphism** | **MAF** |
| **ABCB1** | rs3213619 | **A**/T | 0.419 |
| **ADRB2** | rs2082382 | A/**G** | 0.184 |
| **CAMKK1** | rs7214723 | C/**T** | 0.279 |
| **Chr.1 68392796 on GRCh38** | rs3125923 | C/**T** |  |
| **BCL6 BCL6** | rs1903216 | C/**T** | 0.48 |
| **EPHA5** | rs7349683 | C/**T** | 0.36 |
| **FANCD2** | rs6442150 | **C**/T |  |
| **FANCD2** | rs6786638 | **C**/G | 0.182 |
| **FGD4** | rs10771973 | **A**/G | 0.31 |
| **FZD3** | rs7001034 | **A**/G | 0.398 |
| **GSTP1** | rs1138272 | C/**T** | 0.036 |
| **MAPT** | rs242557 | **A**/G/T |  |
| **mir3194** | rs228832 | A/**G** |  |
| **NDRG1** | rs2233335 | A/**C** | 0.38 |
| **XKR4** | rs4737264 | A/**C** | 0.22 |
| **SNP**: single nucleotide polymorphism; **MAF**: minor allele frequency | | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 2.** Other uncommon Adverse Events– maximum grade | | | | | | | |
| **Toxicity – N=170** | **G0 n (%)** | **G1 n (%)** | **G2 n (%)** | **G3 n (%)** | **G4 n (%)** | **G5 n (%)** | **Severe toxicity**  **(G3+G4+G5) n (%) [%95%CI]** |
| **Blood/bone marrow** | 153 (90.0) | 5 (2.9) | 8 (4.7) | 3 (1.8) | 1 (0.6) | 0 (0.0) | 4 (2.4) [0.65 - 5.91] |
| - Hemoglobin (Hgb) | 158 (92.9) | 4 (2.4) | 7 (4.1) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) |
| - Leukocytes (total) | 167 (98.2) | 1 (0.6) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Lymphopenia | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Neutrophils | 165 (97.1) | 1 (0.6) | 1 (0.6) | 2 (1.2) | 1 (0.6) | 0 (0.0) | 3 (1.8) |
| - Platelets | 167 (98.2) | 3 (1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Transfusion: pRBCs | 169 (99.4) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) |
| **Cardiovascular (general)** | 167 (98.2) | 1 (0.6) | 1 (0.6) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) [0.02 - 3.23] |
| - Edema | 168 (98.8) | 0 (0.0) | 1 (0.6) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) |
| - Hypertension | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Coagulation** | 169 (99.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Fatigue (asthenia) | 169 (99.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Dermatology/skin** | 164 (96.5) | 3 (1.8) | 3 (1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Alopecia | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Erythema multiforme | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Pruritus | 169 (99.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Rash/desquamation | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Dermatology/Skin-Other (Specify in NOTE) | 168 (98.8) | 0 (0.0) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Gastrointestinal** | 145 (85.3) | 17 (10.0) | 5 (2.9) | 3 (1.8) | 0 (0.0) | 0 (0.0) | 3 (1.8) [0.37 - 5.07] |
| - Anorexia | 169 (99.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Diarrhea | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Dyspepsia/heartburn | 167 (98.2) | 2 (1.2) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Dysphagia | 168 (98.8) | 1 (0.6) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Gastritis | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Mouth dryness | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Mucositis | 163 (95.9) | 5 (2.9) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Vomiting | 162 (95.3) | 5 (2.9) | 1 (0.6) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 2 (1.2) |
| - Gastrointestinal-Other (Specify in NOTE) | 163 (95.9) | 6 (3.5) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) |
| **Hemorrhage** | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Hemorrhage-Other  (Specify site in NOTE) | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Hepatic | 159 (93.5) | 3 (1.8) | 3 (1.8) | 4 (2.4) | 1 (0.6) | 0 (0.0) | 5 (2.9) [0.96 - 6.73] |
| - Alkaline phosphatase | 169 (99.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Bilirubin | 169 (99.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - GGT | 168 (98.8) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 1 (0.6) | 0 (0.0) | 2 (1.2) |
| - SGOT (AST) | 161 (94.7) | 6 (3.5) | 2 (1.2) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) |
| - SGPT (ALT) Hepatic-Other (Specify in NOTE) | 162 (95.3) | 5 (2.9) | 1 (0.6) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 2 (1.2) |
| **Infection/febrile neutropenia** | 162 (95.3) | 2 (1.2) | 1 (0.6) | 2 (1.2) | 3 (1.8) | 0 (0.0) | 5 (2.9) [0.96 - 6.73] |
| - Catheter-related infection | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Febrile neutropenia | 168 (98.8) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 1 (0.6) | 0 (0.0) | 2 (1.2) |
| - Infection with grade 3 or 4 neutropenia | 168 (98.8) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 1 (0.6) |
| - Infection without neutropenia | 167 (98.2) | 1 (0.6) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Infection/Febrile Neutropenia-Other  (Specify in NOTE) | 168 (98.8) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 1 (0.6) | 0 (0.0) | 2 (1.2) |
| **Lymphatics** | 168 (98.8) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Lymphedema | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Lymphatics-Other  (Specify in NOTE) | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Metabolic/laboratory** | 163 (95.9) | 2 (1.2) | 3 (1.8) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 2 (1.2) [0.14 - 4.19] |
| - Metabolic/Laboratory-Other (Specify in NOTE) | 163 (95.9) | 2 (1.2) | 3 (1.8) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 2 (1.2) |
| **Musculoskeletal** | 166 (97.6) | 3 (1.8) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Arthritis | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Musculoskeletal-Other (Specify in NOTE) | 167 (98.2) | 2 (1.2) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Neurology** | 163 (95.9) | 4 (2.4) | 3 (1.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Confusion | 167 (98.2) | 2 (1.2) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Depressed level of consciousness | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Dizziness/lightheadedness | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Insomnia | 169 (99.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Memory loss | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Speech impairment  (e.g., dysphasia or aphasia) | 169 (99.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Vertigo | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Neurology-Other  (Specify in NOTE) | 168 (98.8) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Ocular/visual** | 168 (98.8) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Conjunctivitis | 168 (98.8) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Pain** | 137 (80.6) | 22 (12.9) | 7 (4.1) | 4 (2.4) | 0 (0.0) | 0 (0.0) | 4 (2.4) [0.65 - 5.91] |
| - Abdominal pain or cramping | 163 (95.9) | 7 (4.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Arthralgia (joint pain) | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Bone pain | 161 (94.7) | 2 (1.2) | 5 (2.9) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 2 (1.2) |
| - Chest pain  (non-cardiac and non-pleuritic) | 168 (98.8) | 1 (0.6) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) |
| - Headache | 165 (97.1) | 4 (2.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) |
| - Hepatic pain | 169 (99.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Myalgia (muscle pain) | 164 (96.5) | 5 (2.9) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Tumor pain  (onset or exacerbation of tumor pain due to treatment) | 168 (98.8) | 1 (0.6) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Pain-Other  (Specify in NOTE) | 163 (95.9) | 7 (4.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Pulmonary** | 159 (93.5) | 5 (2.9) | 3 (1.8) | 2 (1.2) | 0 (0.0) | 1 (0.6) | 3 (1.8) [0.37 - 5.07] |
| - Cough | 165 (97.1) | 1 (0.6) | 4 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Dyspnea (shortness of breath) | 164 (96.5) | 4 (2.4) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 1 (0.6) | 2 (1.2) |
| - Pleural effusion  (non-malignant) | 169 (99.4) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) |
| - Pneumothorax | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Pulmonary-Other  (Specify in NOTE) | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Renal/genitourinary** | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| - Incontinence | 169 (99.4) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Syndromes (not included in previous categories)** | 158 (92.9) | 5 (2.9) | 6 (3.5) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) [0.02 - 3.23] |
| - Syndromes-Other  (Specify in NOTE) | 158 (92.9) | 5 (2.9) | 6 (3.5) | 1 (0.6) | 0 (0.0) | 0 (0.0) | 1 (0.6) |
| **Legend: N**: Number of subjects; **G**: Grade. **pRBc**: packed red blood cells. | | | | | | | |

|  |
| --- |
| **Supplementary Table 3.** QOL scores – change from baseline to third cycle |

|  | **Baseline (T0)**  Mean (SD) **N=74** | **Third cycle**  Mean (SD) **N=74** | **Difference  3rdcycle-T0 N=74** | **P-value** |
| --- | --- | --- | --- | --- |
| **EORTC QLQ-C30** |  |  |  |  |
| ***Functional scales*** |  |  |  |  |
| Physical Functioning | 74.7 (18.7) | 73.8 (19.2) | -0.9 (15.4) | 0.616 |
| Role Functioning | 73.4 (27.6) | 73.0 (25.5) | -0.5 (20.3) | 0.849 |
| Emotional Functioning | 72.4 (20.2) | 73.2 (20.0) | 0.8 (17.0) | 0.691 |
| Cognitive Functioning | 88.5 (19.7) | 85.8 (19.4) | -2.7 (17.2) | 0.181 |
| Social Functioning | 79.3 (26.1) | 78.2 (26.3) | -1.1 (23.9) | 0.689 |
| **Global health status / QoL** | 55.9 (20.0) | 54.0 (20.0) | -1.9 (17.9) | 0.365 |
| ***Symptom scales / item*** |  |  |  |  |
| Fatigue | 33.2 (24.9) | 38.6 (25.3) | 5.4 (19.7) | 0.021 |
| Nausea / Vomiting | 5.8 (13.3) | 10.2 (19.4) | 4.4 (17.6) | 0.032 |
| Pain | 25.0 (27.9) | 25.2 (27.2) | 0.2 (19.4) | 0.921 |
| Dyspnea | 18.2 (25.9) | 19.6 (25.2) | 1.3 (22.9) | 0.615 |
| Insomnia | 24.4 (30.2) | 23.6 (24.4) | -0.9 (24.5) | 0.754 |
| Appetite loss | 13.5 (23.4) | 15.8 (24.8) | 2.3 (21.6) | 0.373 |
| Constipation | 10.8 (23.5) | 11.3 (23.6) | 0.5 (26.7) | 0.885 |
| Diarrhea | 7.2 (16.8) | 5.4 (14.6) | -1.8 (21.3) | 0.469 |
| Financial Problems | 14.0 (27.0) | 11.3 (25.4) | -2.7 (14.3) | 0.109 |
| **QLQ-BR23** |  |  |  |  |
| ***Functional scales*** |  |  |  |  |
| Body image | 77.8 (30.3) | 71.9 (31.1) | -5.9 (20.7) | 0.019 |
| Sexual functioning | 6.7 (14.7) | 5.6 (13.7) | -1.2 (13.5) | 0.470 |
| Future perspective | 54.0 (31.6) | 57.3 (34.4) | 3.3 (32.4) | 0.396 |
| ***Symptom scales / items*** |  |  |  |  |
| Systematic therapy side effects | 13.8 (15.0) | 20.0 (17.1) | 6.2 (13.8) | <0.001 |
| Breast symptoms | 8.5 (13.0) | 8.1 (11.6) | -0.4 (11.3) | 0.794 |
| Arm symptoms | 14.4 (18.8) | 13.0 (19.1) | -1.4 (11.1) | 0.289 |
| Upset by hair loss | 33.3 (33.3) | 33.3 (33.3) | 0.0 (0.0) | . |
| **Legend:** SD: standard deviation. A high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. | | | | |

|  |
| --- |
| **Supplementary Table 4. QOL scores – change from baseline to end of treatment** |

|  | **Baseline (T0)**  Mean (SD) **N=98** | **End of treatment (EoT)**  Mean (SD) **N=98** | **Difference  EoT-T0 N=98** | **P-value** |
| --- | --- | --- | --- | --- |
| **EORTC QLQ-C30** |  |  |  |  |
| ***Functional scales*** | | | | |
| Physical Functioning | 74.1 (18.8) | 69.2 (22.1) | -4.9 (16.1) | 0.003\* |
| Role Functioning | 72.4 (27.8) | 66.0 (27.7) | -6.5 (20.8) | 0.003\* |
| Emotional Functioning | 72.0 (21.6) | 71.1 (21.3) | -0.9 (18.6) | 0.619 |
| Cognitive Functioning | 86.2 (20.5) | 82.5 (22.8) | -3.7 (20.1) | 0.068 |
| Social Functioning | 76.9 (28.0) | 74.8 (27.9) | -2.0 (26.8) | 0.453 |
| **Global health status / QoL** | 55.9 (20.0) | 50.5 (19.9) | -5.4 (20.2) | 0.010\* |
| ***Symptom scales / item*** | | | | |
| Fatigue | 34.8 (25.1) | 41.2 (25.5) | 6.3 (21.8) | 0.005\* |
| Nausea / Vomiting | 6.1 (12.5) | 6.8 (14.1) | 0.7 (14.3) | 0.640 |
| Pain | 26.4 (27.8) | 29.1 (26.4) | 2.7 (24.0) | 0.265 |
| Dyspnea | 19.7 (26.6) | 25.9 (27.7) | 6.1 (24.1) | 0.014\* |
| Insomnia | 26.9 (29.4) | 28.2 (26.8) | 1.4 (27.5) | 0.625 |
| Appetite loss | 15.0 (23.5) | 17.7 (25.0) | 2.7 (25.2) | 0.287 |
| Constipation | 8.9 (21.3) | 14.8 (24.5) | 5.8 (24.1) | 0.019\* |
| Diarrhea | 7.8 (17.8) | 6.5 (16.3) | -1.4 (22.4) | 0.549 |
| Financial Problems | 13.3 (26.5) | 11.2 (25.3) | -2.0 (15.7) | 0.202 |
| **QLQ-BR23** |  |  |  |  |
| ***Functional scales*** | | | | |
| Body image | 75.7 (31.3) | 73.7 (30.8) | -2.0 (22.7) | 0.385 |
| Sexual functioning | 7.4 (14.8) | 3.2 (9.9) | -4.3 (14.0) | 0.004\* |
| Future perspective | 51.8 (32.3) | 53.9 (34.9) | 2.1 (34.5) | 0.551 |
| ***Symptom scales / items*** | | | | |
| Systematic therapy side effects | 14.7 (14.4) | 21.4 (15.5) | 6.6 (12.7) | <0.001\* |
| Breast symptoms | 10.5 (17.5) | 10.7 (17.1) | 0.2 (12.7) | 0.893 |
| Arm symptoms | 16.2 (19.1) | 16.0 (20.9) | -0.2 (13.7) | 0.868 |
| Upset by hair loss | 33.3 (33.3) | 29.6 (30.9) | -3.7 (20.0) | 0.594 |
| **Legend:** SD: standard deviation. A high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. | | | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **Supplementary Table 5. Frequency of variants of all the 15 SNPs and the prevalence of each polymorphism was compared with the expected prevalence in Europe** | | | |
|  | **OVERALL**  **N=159** | **EUROPE**  **Genotype %** | **Chi-squared GOF test**  **P-value** |
| **rs1138272 - GSTP1 - n (%)** | | | |
| C/C | 140 (88.6) | 85.9 | 0.444\* |
| C/T | 16 (10.1) | 14.1 |  |
| T/T | 2 (1.3) | 0 |  |
| Missing | 1 |  |  |
| **rs1903216 - close to Bcl6 - n (%)** | | | |
| A/A | 48 (30.4) | 22.3 | 0.204 |
| A/G | 73 (46.2) | 53.3 |  |
| G/G | 37 (23.4) | 24.5 |  |
| Missing | 1 |  |  |
| **rs2082382 ADRB2 - n (%)** | | | |
| A/A | 68 (43.0) | 33.8 | 0.028# |
| A/G | 75 (47.5) | 51.9 |  |
| G/G | 15 (9.5) | 14.3 |  |
| Missing | 1 |  |  |
| **rs7001034 - FZD3 - n (%)** | | | |
| A/A | 19 (12.0) | 15.5 | 0.473 |
| A/G | 76 (48.1) | 46.9 |  |
| G/G | 63 (39.9) | 37.6 |  |
| Missing | 1 |  |  |
| **rs6786638 - FANCD2 - n (%)** | | | |
| C/C | 5 (3.1) | 2.4 | 0.356\* |
| C/G | 44 (27.7) | 23.5 |  |
| G/G | 110 (69.2) | 74.2 |  |
| **rs228832 - mir3194 - n (%)** | | | |
| C/C | 92 (57.9) | 59.6 | 0.511 |
| C/T | 54 (34.0) | 34.4 |  |
| T/T | 13 (8.2) | 6 |  |
| **rs10771973 - FGD4 - n (%)** | | | |
| A/A | 25 (16.0) | 10.1 | 0.039# |
| A/G | 60 (38.5) | 43.9 |  |
| G/G | 71 (45.5) | 45.9 |  |
| Missing | 3 |  |  |
| **rs4737264 - XKR4 - n (%)** | | | |
| A/A | 108 (68.8) | 64 | 0.402 |
| A/C | 45 (28.7) | 32.2 |  |
| C/C | 4 (2.5) | 3.8 |  |
| Missing | 2 |  |  |
| **rs3125923 Chr.1 68392796 on GRCh38 - n (%)** | | | |
| A/A | 124 (78.5) | 73.8 | 0.362\* |
| A/G | 31 (19.6) | 24.5 |  |
| G/G | 3 (1.9) | 1.8 |  |
| Missing | 1 |  |  |
| **rs7349683 - EPHA5 - n (%)** | | | |
| C/C | 72 (45.3) | 37.4 | 0.118 |
| C/T | 69 (43.4) | 50.3 |  |
| T/T | 18 (11.3) | 12.3 |  |
| **rs2233335 - NDRG1 - n (%)** | | | |
| G/G | 32 (20.1) | 13.1 | 0.029# |
| G/T | 70 (44.0) | 46.1 |  |
| T/T | 57 (35.8) | 40.8 |  |
| **rs7214723 - CAMKK1 - n (%)** | | | |
| C/C | 47 (29.9) | 20.5 | 0.014# |
| C/T | 66 (42.0) | 47.7 |  |
| T/T | 44 (28.0) | 31.8 |  |
| Missing | 2 |  |  |
| **rs3213619 - ABCB1 - n (%)** | | | |
| A/A | 147 (93.0) | 92.4 | 0.834\* |
| A/G | 11 (7.0) | 7.4 |  |
| G/G | 0 (0.0) | 0.2 |  |
| Missing | 1 |  |  |
| **rs6442150 - FANCD2 - n (%)** | | | |
| C/C | 5 (3.2) | 2.4 | 0.365\* |
| C/T | 43 (27.6) | 23.5 |  |
| T/T | 108 (69.2) | 74.2 |  |
| Missing | 3 |  |  |
| **rs242557 - MAPT - n (%)** | | | |
| A/A | 9 (5.7) | 13.7 | 0.004# |
| A/G | 77 (48.7) | 49.7 |  |
| G/G | 72 (45.6) | 36.6 |  |
| Missing | 1 |  |  |
| **Legend: N**: Number of subjects. **GOF**: Goodness Of Fit. **\***: The Chi-square approximation could be inaccurate.  **#**:P-value<0.05 | | | |